N,N'-Bis(salicylidene)ethylenediamineCAS# 94-93-9 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 94-93-9 | SDF | Download SDF |
PubChem ID | 5379013 | Appearance | Powder |
Formula | C16H16N2O2 | M.Wt | 268.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (6Z)-6-[[2-[[(Z)-(6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]ethylamino]methylidene]cyclohexa-2,4-dien-1-one | ||
SMILES | C1=CC(=CNCCNC=C2C=CC=CC2=O)C(=O)C=C1 | ||
Standard InChIKey | RQHVNNWVDLRULK-XSYHWHKQSA-N | ||
Standard InChI | InChI=1S/C16H16N2O2/c19-15-7-3-1-5-13(15)11-17-9-10-18-12-14-6-2-4-8-16(14)20/h1-8,11-12,17-18H,9-10H2/b13-11-,14-12- | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
N,N'-Bis(salicylidene)ethylenediamine Dilution Calculator
N,N'-Bis(salicylidene)ethylenediamine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.7272 mL | 18.6359 mL | 37.2717 mL | 74.5434 mL | 93.1793 mL |
5 mM | 0.7454 mL | 3.7272 mL | 7.4543 mL | 14.9087 mL | 18.6359 mL |
10 mM | 0.3727 mL | 1.8636 mL | 3.7272 mL | 7.4543 mL | 9.3179 mL |
50 mM | 0.0745 mL | 0.3727 mL | 0.7454 mL | 1.4909 mL | 1.8636 mL |
100 mM | 0.0373 mL | 0.1864 mL | 0.3727 mL | 0.7454 mL | 0.9318 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Piperine
Catalog No.:BCN1018
CAS No.:94-62-2
- 2-Amino-6-ethoxybenzothiazole
Catalog No.:BCC8541
CAS No.:94-45-1
- Benzyl nicotinate
Catalog No.:BCC8874
CAS No.:94-44-0
- Butylparaben
Catalog No.:BCN8418
CAS No.:94-26-8
- Tetracaine
Catalog No.:BCC9175
CAS No.:94-24-6
- Chlorpropamide
Catalog No.:BCC4647
CAS No.:94-20-2
- Benzyl 4-hydroxybenzoate
Catalog No.:BCC8869
CAS No.:94-18-8
- Sodium 4-amiropparaty Hyalrate
Catalog No.:BCC3855
CAS No.:94-16-6
- Propylparaben
Catalog No.:BCN8416
CAS No.:94-13-3
- Benzocaine
Catalog No.:BCC4636
CAS No.:94-09-7
- Synephrine
Catalog No.:BCN6308
CAS No.:94-07-5
- p53 and MDM2 proteins-interaction-inhibitor racemic
Catalog No.:BCC1831
CAS No.:939983-14-9
- NVP-BHG712
Catalog No.:BCC3963
CAS No.:940310-85-0
- Suplatast Tosylate
Catalog No.:BCC4961
CAS No.:94055-76-2
- Poliumoside
Catalog No.:BCN1204
CAS No.:94079-81-9
- R-7128
Catalog No.:BCC1880
CAS No.:940908-79-2
- SB743921
Catalog No.:BCC4559
CAS No.:940929-33-9
- KD 5170
Catalog No.:BCC2420
CAS No.:940943-37-3
- 1'-Acetonaphthone
Catalog No.:BCC8446
CAS No.:941-98-0
- 1,3,5-Cadinatriene-3,8-diol
Catalog No.:BCN4486
CAS No.:941227-27-6
- Selaginellin
Catalog No.:BCN8215
CAS No.:941269-84-7
- Ruxolitinib (INCB018424)
Catalog No.:BCC1276
CAS No.:941678-49-5
- INCB032304
Catalog No.:BCC6455
CAS No.:941685-27-4
- S-Ruxolitinib (INCB018424)
Catalog No.:BCC2201
CAS No.:941685-37-6
Treatment of oral cancer using magnetized paclitaxel.[Pubmed:29643995]
Oncotarget. 2018 Feb 26;9(21):15591-15605.
N,N'-Bis(salicylidene)ethylenediamine iron (Fe(Salen)) is an anti-cancer agent with intrinsic magnetic property. Here, we covalently linked Fe(Salen) to paclitaxel (PTX), a widely used anti-cancer drug, to obtain a magnetized paclitaxel conjugate (M-PTX), which exhibited magnetic characteristics for magnet-guided drug delivery and MRI visualization. M-PTX increased apoptosis and G2/M arrest of cultured human oral cancer cell lines in the same manner as PTX. Furthermore, marked contrast intensity was obtained in magnetic resonance imaging (MRI) of M-PTX. In a mouse oral cancer model, a permanent magnet placed on the body surface adjacent to the tumor resulted in distinct accumulation of M-PTX, and the anti-cancer effect was greater than that of M-PTX without the magnet. We believe that this strategy may improve future cancer chemotherapy by providing conventional anti-cancer drugs with novel functionalities such as magnet-guided drug delivery or MRI-based visualization/quantitation of drug distribution.